BioMarin Pharmaceutical retained earnings (accumulated deficit) for the quarter ending December 31, 2024 were $-0.195B, a 68.68% decline year-over-year.
BioMarin Pharmaceutical retained earnings (accumulated deficit) for 2024 were $-0.195B, a 68.68% decline from 2023.
BioMarin Pharmaceutical retained earnings (accumulated deficit) for 2023 were $-0.622B, a 21.24% decline from 2022.
BioMarin Pharmaceutical retained earnings (accumulated deficit) for 2022 were $-0.789B, a 15.21% decline from 2021.